Regeneron Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference Transcript
Hi, everybody, and thank you for joining us for this session of the SEC with Len Schleifer, CEO of Regeneron; and the IR team. I'm Ronny Gal, the -- I guess, biopharma analyst here at Bernstein. Len is with us fresh -- very fresh after, I guess, 2 days of talking to investors with the offering that rather came out in the last couple of days. I just learned it's the largest offering in the sector for a very, very long time. And that has gone through successfully. So congratulation, Len and the IR team. So a little bit of a post that set of issues, we have a nice time for us to discuss the business and how it looks forwards with potentially some new people who are now fresh investors in the company.
For those of you who have joined us, the investors, I want to mention to you that there's an interactive Q&A format that we're using here, called Pigeonhole. There's a link on the left side of your screen to access that application. When you click on the link, it will open up as a new window, and you can see
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |